Table 1 |
||
|
Preferred chemotherapy and endocrine agents and regimens for HER2-negative metastatic breast cancer |
||
|
Type of therapy |
Type of regimen/class of agent |
Agents |
|
|
||
|
Cytotoxic chemotherapiesa |
Single agents |
Anthracyclines: doxorubicin (A), epirubicin (E), pegylated liposomal doxorubicin Taxanes: paclitaxel (T), docetaxel (T), nab-paclitaxel Fluoropyrimidines: capecitabine Others: vinorelbine, gemcitabine (G) |
|
Combination chemotherapy |
Anthracycline based: CAF/FAC, FEC, AC, EC Taxane-based: T/cisplatin, TG, T/carboplatin, T/capecitabine Anthracycline/taxane: AT Other: CMF |
|
|
Combinations with targeted or specific anti-VEGF agents |
Bevacizumab + paclitaxel |
|
|
Endocrine therapies |
Aromatase inhibitors |
Steroidal (type I): exemestane Nonsteroidal (type II): anastrozole, letrozole |
|
SERMs (anti-oestrogens) |
Tamoxifen Toremifene |
|
|
SERD |
Fulvestrant |
|
|
Progestin |
Megestrol acetate |
|
|
Androgen |
Fluoxymesterone |
|
|
High-dose oestrogen |
Ethinylestradiol |
|
|
|
||
|
Adapted from Beslija and coworkers [1] and the National Comprehensive Cancer Network [2]. aAdditional active agents are as follows: oral etoposide, vinblastine, 5-fluorouracil (F) continuous infusion, ixabepilone, and ixabepilone plus capecitabine. AC, doxorubicin, cyclophosphamide; CMF, cyclophosphamide, methotrexate, 5-fluorouracil; EC, epirubicin, cyclophosphamide; FAC/CAF, 5-fluorouracil, doxorubicin, cyclophosphamide; FEC, 5-fluorouracil, epirubicin, cyclophosphamide; HER2, human epidermal growth factor receptor 2; SERD, selective oestrogen receptor downregulator; SERM, selective oestrogen receptor modulator; VEGF, vascular endothelial growth factor. |
||
|
Miles Breast Cancer Research 2009 11:208 doi:10.1186/bcr2237 |
||